Richard Byrd Sells 459 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Richard Byrd sold 459 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares in the company, valued at $1,598,960. This represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard Byrd also recently made the following trade(s):

• On Wednesday, March 12th, Richard Byrd sold 1,940 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $224.91, for a total value of $436,325.40.

Becton, Dickinson and Company Stock Up 0.1 %

Shares of NYSE:BDX opened at $231.94 on Friday. The company’s fifty day moving average is $232.64 and its two-hundred day moving average is $232.12. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The stock has a market capitalization of $66.60 billion, a price-to-earnings ratio of 38.53, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.79%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds have recently added to or reduced their stakes in the stock. Bank of Jackson Hole Trust acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $25,000. REAP Financial Group LLC grew its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the last quarter. Sierra Ocean LLC acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management raised its holdings in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the last quarter. Finally, Hopwood Financial Services Inc. acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $39,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on BDX shares. Piper Sandler upped their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, March 5th. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.